Medicines for Heart Disease
Development of potential medical preparations for treatment of hyper beta-lipoproteinemia atherosclerosis and heart disease.
Tech Area / Field
- MED-DRG/Drug Discovery/Medicine
8 Project completed
Senior Project Manager
Tyurin I A
State Research Institute of Organic Chemistry and Technology, Russia, Moscow
- US Department of Health & Human Services / National Institute of Health, USA, MD, Bethesda
Project summaryAtherosclerosis is one of the lost widespread and severe diseases of the cardio-vascular system; its complications (myocardial infarction, insult, thromboses, coronary heart disease) constitute the lain reason of lethality and loss of the capacity for work in inpiduals over 40 years old.
fit present, there are no sufficiently effective and cheap medicines to treat atherosclerosis and diseases proioting its development (hyper-b-lipoproteinemia).
This design is ailed at development of new medicinal agents intended for treatment of hyper-b-lipoproteinemia, atherosclerosis and coronary heart disease.
The suggested approach is based on regulation of the activity of butyrylcholinesterase (ChE), one of the enzymes promoting the formation of b-lipoproteins which are the main carriers of cholesterol in the human organism.
To regulate the ChE activity, we intend to use highly specific ChE inhibitors containing cyclic fragments NCCO and NCCS. The fact that this trend of search for medicinal agents is promising was demonstrated in a number of foreign and homemade works, as well as in developments of the SRIOCT. The suggested result of the study would be development of effective medicines active in considerably lower dosages as compared to those available to date.
The proposed program of study will comprise 3 stages and each of these stages is of certain scientific and practical value.
THE FIRST STAGE comprises finding of highly specific ChE inhibitors which lay be used in various biological and biochemical investigations.
THE SECOND STAGE will involve the study of useful properties of highly specific ChE inhibitors and will be ailed at revealing substances which lower the content of (b-lipoproteins in the blood of the homoiothermal fit for various biological and biochemical investigations.
THE THIRD STAGE will involve the estimation of a possible use of the given substances as medicinal agents.
To obtain desired substances, the procedures developed at the SRIOCT and not described in literature for introduction of NCCO and NCCS cyclic fragments which allow to obtain desired substances with high yields would be used. This significantly will simplify their production and will make it more cheap both in the laboratory and on an industrial scale.
The personnel of the SRIOCT have a unique experience in the study of inhibitors of cholinesterases and their influence on the organism of the warm-blooded animals.